Royce & Associates LP Innoviva, Inc. Transaction History

Royce & Associates LP

  • $10.5 Billion
  • Q3 2024

A detailed history of Royce & Associates LP transactions in Innoviva, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 57,908 shares of INVA stock, worth $1.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
57,908
Previous 44,494 30.15%
Holding current value
$1.11 Million
Previous $729,000 53.22%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024
BUY
$16.33 - $20.04 $219,050 - $268,816
13,414 Added 30.15%
57,908 $1.12 Million
Q2 2024

Aug 13, 2024
SELL
$14.4 - $16.4 $354,412 - $403,636
-24,612 Reduced 35.61%
44,494 $729,000
Q1 2024

May 13, 2024
SELL
$14.56 - $16.78 $219,433 - $252,891
-15,071 Reduced 17.9%
69,106 $1.05 Million
Q4 2023

Feb 12, 2024
SELL
$12.32 - $16.27 $398,835 - $526,708
-32,373 Reduced 27.78%
84,177 $1.35 Million
Q3 2023

Nov 09, 2023
SELL
$12.37 - $13.89 $22,439 - $25,196
-1,814 Reduced 1.53%
116,550 $1.51 Million
Q2 2023

Aug 07, 2023
BUY
$11.39 - $13.72 $10,752 - $12,951
944 Added 0.8%
118,364 $1.51 Million
Q1 2023

May 04, 2023
BUY
$10.73 - $13.6 $193,719 - $245,534
18,054 Added 18.17%
117,420 $1.32 Million
Q4 2022

May 23, 2023
SELL
$11.8 - $13.78 $213,037 - $248,784
-18,054 Reduced 15.38%
99,366 $1.32 Million
Q4 2022

Feb 13, 2023
BUY
$11.8 - $13.78 $214,229 - $250,175
18,155 Added 22.36%
99,366 $1.32 Million
Q3 2022

Nov 03, 2022
BUY
$11.61 - $15.22 $33,831 - $44,351
2,914 Added 3.72%
81,211 $943,000
Q2 2022

Aug 04, 2022
SELL
$14.32 - $19.88 $31,389 - $43,576
-2,192 Reduced 2.72%
78,297 $1.16 Million
Q1 2022

May 05, 2022
SELL
$15.39 - $20.25 $161,164 - $212,058
-10,472 Reduced 11.51%
80,489 $1.56 Million
Q4 2021

Feb 07, 2022
BUY
$15.91 - $18.72 $73,186 - $86,112
4,600 Added 5.33%
90,961 $1.57 Million
Q3 2021

Nov 10, 2021
BUY
$13.06 - $17.24 $14,117 - $18,636
1,081 Added 1.27%
86,361 $1.44 Million
Q2 2021

Aug 06, 2021
BUY
$11.45 - $13.96 $32,483 - $39,604
2,837 Added 3.44%
85,280 $1.14 Million
Q1 2021

May 10, 2021
BUY
$11.06 - $12.87 $41,231 - $47,979
3,728 Added 4.74%
82,443 $985,000
Q4 2020

Feb 08, 2021
BUY
$9.33 - $12.48 $19,509 - $26,095
2,091 Added 2.73%
78,715 $975,000
Q3 2020

Nov 12, 2020
BUY
$10.33 - $14.49 $7,602 - $10,664
736 Added 0.97%
76,624 $801,000
Q2 2020

Aug 07, 2020
BUY
$11.49 - $15.26 $2,366 - $3,143
206 Added 0.27%
75,888 $1.06 Million
Q1 2020

May 12, 2020
SELL
$8.11 - $15.23 $2,165 - $4,066
-267 Reduced 0.35%
75,682 $890,000
Q4 2019

Feb 06, 2020
BUY
$10.28 - $14.38 $154,857 - $216,620
15,064 Added 24.74%
75,949 $1.08 Million
Q3 2019

Nov 13, 2019
BUY
$10.05 - $14.55 $263,239 - $381,108
26,193 Added 75.5%
60,885 $642,000
Q2 2019

Aug 12, 2019
BUY
$13.1 - $14.95 $195,766 - $223,412
14,944 Added 75.67%
34,692 $505,000
Q1 2019

May 09, 2019
BUY
$13.69 - $20.06 $252,566 - $370,086
18,449 Added 1420.25%
19,748 $277,000
Q4 2018

Feb 11, 2019
SELL
$13.96 - $18.26 $8,585 - $11,229
-615 Reduced 32.13%
1,299 $23,000
Q3 2018

Nov 13, 2018
BUY
$13.63 - $15.7 $9,799 - $11,288
719 Added 60.17%
1,914 $29,000
Q2 2018

Aug 09, 2018
BUY
$13.44 - $17.59 $7,015 - $9,181
522 Added 77.56%
1,195 $16,000
Q1 2018

May 14, 2018
SELL
$13.8 - $16.99 $2,401 - $2,956
-174 Reduced 20.54%
673 $11,000
Q4 2017

Feb 09, 2018
BUY
$11.73 - $14.75 $1,067 - $1,342
91 Added 12.04%
847 $12,000
Q3 2017

Nov 13, 2017
BUY
$12.06 - $14.12 $9,117 - $10,674
756
756 $11,000

Others Institutions Holding INVA

# of Institutions
229
Shares Held
79.2M
Call Options Held
37.6K
Put Options Held
300
View Full List

About Innoviva, Inc.

INVA Quotes by TradingView
  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.33B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email